Previous close | 70.13 |
Open | 70.40 |
Bid | 70.80 x 400 |
Ask | 70.87 x 400 |
Day's range | 70.16 - 71.10 |
52-week range | 60.47 - 75.75 |
Volume | |
Avg. volume | 6,186,954 |
Market cap | 219.666B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 37.09 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.45 (2.05%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
Key Insights Given the large stake in the stock by institutions, AstraZeneca's stock price might be vulnerable to their...
Beyond analysts' top -and-bottom-line estimates for Astrazeneca (AZN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.